Cargando…

Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial

PURPOSE: The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacodynamic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with liver metastasis (CRCLM). MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yeo-Eun, Joo, Bio, Park, Mi-Suk, Shin, Sang Joon, Ahn, Joong Bae, Kim, Myeong-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080817/
https://www.ncbi.nlm.nih.gov/pubmed/26987390
http://dx.doi.org/10.4143/crt.2015.374
_version_ 1782462803215384576
author Kim, Yeo-Eun
Joo, Bio
Park, Mi-Suk
Shin, Sang Joon
Ahn, Joong Bae
Kim, Myeong-Jin
author_facet Kim, Yeo-Eun
Joo, Bio
Park, Mi-Suk
Shin, Sang Joon
Ahn, Joong Bae
Kim, Myeong-Jin
author_sort Kim, Yeo-Eun
collection PubMed
description PURPOSE: The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacodynamic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with liver metastasis (CRCLM). MATERIALS AND METHODS: From July 2011 to March 2012, 28 patients with histologically confirmed CRCLM received bevacizumab monotherapy followed by combined FOLFOX therapy. The mean age of the patients was 57 years (range, 30 to 77 years). DCE-MRI (K(trans)and IAUC(60)) was performed at baseline, first follow-up (3 days after bevacizumab monotherapy), and second follow-up (3 days after combined therapy). CAF levels (vascular endothelial growth factor [VEGF], placental growth factor [PlGF], and interleukin-8) were assessed on the same days. Progression-free survival (PFS) time distributions were summarized using the Kaplan-Meier method and compared using log-rank tests. RESULTS: The median PFS period was 11.2 months. K(trans), IAUC(60), VEGF, and PlGF values on the first follow-up day were significantly different compared with baseline values. No differences were observed on the second follow-up day. A > 40% decrease in K(trans) from baseline to first follow-up was associated with a longer PFS (hazard ratio, 0.349; 95% confidence interval, 0.133 to 0.912; p=0.032). Changes in CAFs did not show correlation with PFS time. CONCLUSION: DCE-MRI parameters and CAFs are pharmacodynamic biomarkers of bevacizumab for CRCLM. In our study, change in K(trans) at 3 days after bevacizumab monotherapy was a favorable prognostic factor; however, the value of CAFs as a prognostic biomarker was not found.
format Online
Article
Text
id pubmed-5080817
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-50808172016-11-03 Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial Kim, Yeo-Eun Joo, Bio Park, Mi-Suk Shin, Sang Joon Ahn, Joong Bae Kim, Myeong-Jin Cancer Res Treat Original Article PURPOSE: The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacodynamic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with liver metastasis (CRCLM). MATERIALS AND METHODS: From July 2011 to March 2012, 28 patients with histologically confirmed CRCLM received bevacizumab monotherapy followed by combined FOLFOX therapy. The mean age of the patients was 57 years (range, 30 to 77 years). DCE-MRI (K(trans)and IAUC(60)) was performed at baseline, first follow-up (3 days after bevacizumab monotherapy), and second follow-up (3 days after combined therapy). CAF levels (vascular endothelial growth factor [VEGF], placental growth factor [PlGF], and interleukin-8) were assessed on the same days. Progression-free survival (PFS) time distributions were summarized using the Kaplan-Meier method and compared using log-rank tests. RESULTS: The median PFS period was 11.2 months. K(trans), IAUC(60), VEGF, and PlGF values on the first follow-up day were significantly different compared with baseline values. No differences were observed on the second follow-up day. A > 40% decrease in K(trans) from baseline to first follow-up was associated with a longer PFS (hazard ratio, 0.349; 95% confidence interval, 0.133 to 0.912; p=0.032). Changes in CAFs did not show correlation with PFS time. CONCLUSION: DCE-MRI parameters and CAFs are pharmacodynamic biomarkers of bevacizumab for CRCLM. In our study, change in K(trans) at 3 days after bevacizumab monotherapy was a favorable prognostic factor; however, the value of CAFs as a prognostic biomarker was not found. Korean Cancer Association 2016-10 2016-03-17 /pmc/articles/PMC5080817/ /pubmed/26987390 http://dx.doi.org/10.4143/crt.2015.374 Text en Copyright © 2016 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Yeo-Eun
Joo, Bio
Park, Mi-Suk
Shin, Sang Joon
Ahn, Joong Bae
Kim, Myeong-Jin
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
title Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
title_full Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
title_fullStr Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
title_full_unstemmed Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
title_short Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
title_sort dynamic contrast-enhanced magnetic resonance imaging as a surrogate biomarker for bevacizumab in colorectal cancer liver metastasis: a single-arm, exploratory trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080817/
https://www.ncbi.nlm.nih.gov/pubmed/26987390
http://dx.doi.org/10.4143/crt.2015.374
work_keys_str_mv AT kimyeoeun dynamiccontrastenhancedmagneticresonanceimagingasasurrogatebiomarkerforbevacizumabincolorectalcancerlivermetastasisasinglearmexploratorytrial
AT joobio dynamiccontrastenhancedmagneticresonanceimagingasasurrogatebiomarkerforbevacizumabincolorectalcancerlivermetastasisasinglearmexploratorytrial
AT parkmisuk dynamiccontrastenhancedmagneticresonanceimagingasasurrogatebiomarkerforbevacizumabincolorectalcancerlivermetastasisasinglearmexploratorytrial
AT shinsangjoon dynamiccontrastenhancedmagneticresonanceimagingasasurrogatebiomarkerforbevacizumabincolorectalcancerlivermetastasisasinglearmexploratorytrial
AT ahnjoongbae dynamiccontrastenhancedmagneticresonanceimagingasasurrogatebiomarkerforbevacizumabincolorectalcancerlivermetastasisasinglearmexploratorytrial
AT kimmyeongjin dynamiccontrastenhancedmagneticresonanceimagingasasurrogatebiomarkerforbevacizumabincolorectalcancerlivermetastasisasinglearmexploratorytrial